FINWIRES · TerminalLIVE
FINWIRES

$HAE

6 stories mentioning HAEUpdated just now

Every FINWIRES story that references HAE, newest first.

Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetics (HAE) shares jumped past 16% after the company said it entered into a supply agreement with CSL Plasma last week.Pfizer (PFE) was Smart Insider's stock pick of the week after Chief Executive and Chair Albert Bourla bought 38,000 shares for $1 million at $26.34 apiece on Aug. 12. Bourla, who has been with Pfizer since 1993 and has served as CEO since January 2020, increased his holding by 10% to $11.6 million with his first reported purchase, Smart Insider said in a Tuesday note. Pfizer shares rose 1.5%.Amylyx Pharmaceuticals (AMLX) shares surged 63% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.GE HealthCare (GEHC) has appointed William Grogan as chief financial officer, effective Sept. 14, the company said Tuesday. Grogan succeeds Jay Saccaro, who stepped down to pursue another opportunity outside the medical technology industry, the company said. GE HealthCare shares were up 0.6%.

$AMLX$GEHC$HAE$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Haemonetics (HAE) shares jumped past 16% after the company said it entered into a supply agreement with CSL Plasma last week.

$HAE
Wire

Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma

Haemonetics (HAE) shares were up more than 17% in afternoon trading on Tuesday after the company said it entered into a supply agreement with CSL Plasma last week.The deal involves Haemonetics' NexSys PCS plasma collection system with Persona Plus Technology, an automated cell separator system, along with related disposables in the US, according to a Tuesday filing.CSL is expected to transition a portion of its US plasma collection centers to Haemonetics' devices and disposables, but the scope and timing of the implementation are still to be determined, the company said.Price: $105.99, Change: $+15.72, Percent Change: +17.41%

$HAE
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) declined 1.6%.In corporate news, Haemonetics (HAE) updated its financial reporting structure and will transition to two segments from three starting in Q1 fiscal 2027. The stock rose 1.8%.BioCardia (BCDA) received confirmation from the US Food and Drug Administration that its ongoing trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed 23%.CareCloud (CCLD) said shareholders approved all proposals put forward at the annual investor meeting on Thursday, including the re-election of Mahmud Haq and Cameron Munter to the board. CareCloud shares fell 1.5%.Vivos Therapeutics (VVOS) entered a deal with its senior secured lender, Streeterville Capital, to exchange up to $4.5 million of its outstanding debt for a combination of perpetual, nonconvertible preferred stock and shares. Vivos shares climbed 27%.

$BCDA$CCLD$HAE$VVOS
Wire

Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says

Haemonetics (HAE) is positioned for potential upside as the company has issued conservative fiscal 2027 guidance across its core segments Plasma, Hospital, and Blood Center, BofA Securities said in a note Friday.Analysts highlighted strong plasma collection trends, with US volumes rising high single digits in fiscal Q4, indicating potential upside if momentum continues.In the Hospital segment, the investment firm said vascular closure is improving with stronger commercial execution and blood management technologies are expected to remain a steady growth driver.Some upside is also likely in the Blood Center segment, where management has guided for a mid-single-digit decline, BofA said.Analysts cited potential catalysts, including Japan label expansion for vascular closure, the Japanese Red Cross plasma transition, possible tariff relief, and new products such as Vivasure's PerQseal Elite, with additional plasma innovation potentially supporting growth beyond 2027.BofA upgraded Haemonetics stock to buy from neutral, and raised its price target to $80 from $72.Shares of Haemonetics were up 2.7% in Friday trading.Price: $63.64, Change: $+1.70, Percent Change: +2.74%

$HAE
Research

BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80

Haemonetics (HAE) has an average rating of overweight and mean price target of $81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$HAE

Track with the FINWIRES app suite

FolioX
FolioX
Track HAE in your portfolio
WheelAI
WheelAI
Analyze HAE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HAE